Skip to main content
. Author manuscript; available in PMC: 2017 May 1.
Published in final edited form as: Cancer Immunol Res. 2016 Feb 19;4(5):441–451. doi: 10.1158/2326-6066.CIR-15-0104

Figure 2. Sequestration of sTNF by DN-TNF and neutralization of both sTNF and tmTNF by TNFR2-Fc affect secretion of immunoregulatory cytokines in MCA-injected mice.

Figure 2

Healthy/untreated (Control), MCA-injected/PBS-treated (MCA/PBS), MCA-injected/ENBREL-treated (MCA/ENBREL) and MCA-injected/XPro1595-treated (MCA/DN-TNF) wild-type mice (3 mice per each group) were sacrificed and their sera obtained 14 days after MCA-injection. Sera were examined for the presence of IL1β (A), IL12p40/70 (B), IL17 (C), and IL1α (D) using the LUMINEX assay. The data represent mean values of triplicates ± SE. In (A), (B), and (C) the increases of cytokine levels in the sera of MCA/DN-TNF-treated mice were significant relative to that of Control and MCA/PBS-treated mice (P = 0.026, P = 0.05 and P = 0.039, respectively). In (D), the decreases of IL1α levels in the sera of MCA/ENBREL- and DN-TNF-treated mice vs Control and MCA/PBS-treated mice are significant (P = 0.012 and P = 0.023, respectively).